Compare ABVE & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVE | SGMO |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 131.2M |
| IPO Year | N/A | 2000 |
| Metric | ABVE | SGMO |
|---|---|---|
| Price | $1.57 | $0.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 1.8M | ★ 8.5M |
| Earning Date | 07-09-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,446,206.00 | $32,875,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.35 |
| 52 Week High | $6.56 | $1.24 |
| Indicator | ABVE | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 45.63 |
| Support Level | $1.69 | $0.37 |
| Resistance Level | $2.17 | $0.40 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 0.93 | 15.69 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.